Showing 2741-2750 of 5646 results for "".
- Novartis Completes Acquisition of Xiidrahttps://modernod.com/news/novartis-completes-acquisition-of-xiidra-bolstering-ophthalmic-portfolio/2476707/Novartis announced that it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. In May, Novartis agreed to acquire Xiidr
- Ocular Therapeutix Announces Commercial Launch of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-commercial-launch-of-dextenza/2476704/Ocular Therapeutix announced the commercial launch in the United States of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of ocular inflammation and pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert that enables the delivery of drug
- VSP Global Enters Into Definitive Agreement To Acquire Visionworkshttps://modernod.com/news/vsp-global-enters-into-definitive-agreement-to-acquire-visionworks/2476699/VSP Global announced that it has entered into a definitive agreement to acquire San Antonio, Texas-based Visionworks, which has more than 700 stores in 40 states. The Visionworks acquisition will be the single largest VSP network investment in the company’s
- Aldeyra Therapeutics Phase 3 SOLACE Trial Fails to Meet Primary Endpoint in Noninfectious Anterior Uveitishttps://modernod.com/news/aldeyra-therapeutics-phase-3-solace-trial-fails-to-meet-primary-endpoint-in-noninfectious-anterior-uveitis/2476691/Aldeyra Therapeutics announced results from the noninfectious anterior uveitis SOLACE trial. Statistical significance was not achieved for the primary or secondary endpoints, due to high rates of disease resolution in vehicle-treated patients, but activity of reproxalap was consistently greater t
- AbbVie to Buy Allergan in Deal Worth $63 Billionhttps://modernod.com/news/abbvie-to-buy-allergan-in-deal-worth-63-billion/2476686/A blockbuster merger of two large pharma companies will have an impact on the eye care market as AbbVie announced its plans to buy Allergan in a deal worth $63 billion. Under the agreed terms, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share they h
- Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Deliveryhttps://modernod.com/news/alnylam-announces-progress-with-rnai-therapeutics-platform-including-oral-route-of-administration-and-cns-and-ocular-delivery/2476682/Alnylam Pharmaceuticals announced new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target. Oral delivery could broaden the clinical
- Carl Zeiss Meditec Announces Investment in Early Stage MIGS Device Maker MicroOptxhttps://modernod.com/news/carl-zeiss-meditec-announces-investment-in-clinical-stage-migs-device-maker-microoptx/2476679/Carl Zeiss Meditec announced that it has become a shareholder of MicroOptx, a privately held company focused on minimally invasive glaucoma surgery (MIGS) devices for surgical treatment of glaucoma. Their surgical tec
- Alimera’s Iluvien Receives Positive NICE Recommendation for Noninfectious Posterior Uveitishttps://modernod.com/news/alimeras-iluvien-receives-positive-nice-recommendation-for-noninfectious-posterior-uveitis/2476675/Alimera Sciences announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE), in its Final Appraisal Determination for national reimbursement, has recommended funding for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse
- Bausch + Lomb Ultra Multifocal for Astigmatism Contact Lenses Now Available In the United Stateshttps://modernod.com/news/bausch-lomb-ultra-multifocal-for-astigmatism-contact-lenses-now-available-in-the-united-states/2476671/Bausch + Lomb announced the US launch of Bausch + Lomb Ultra Multifocal for Astigmatism contact lenses. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision n
- New Survey Highlights Growing Insurance Problem That Delays Sight-Saving Carehttps://modernod.com/news/new-survey-highlights-growing-insurance-problem-that-delays-sight-saving-care/2476670/The majority of ophthalmologists in a new survey said that a cost-management tool required by health insurance companies is delaying or disrupting the sight-saving care they give their patients. The tool is called prior authorization. Insurance companies use it to control costs by reducing medica